Arie S. Belldegrun
阿里·贝尔德格伦
MD
Professor of Urology, UCLA; Founder & Former CEO, Kite PharmaUCLA泌尿外科学教授；Kite Pharma创始人兼前首席执行官
👥Biography 个人简介
Arie Belldegrun founded Kite Pharma and spearheaded the development and commercialization of axicabtagene ciloleucel (Yescarta), the first CAR-T therapy approved for large B cell lymphoma. The landmark ZUMA-1 trial he championed transformed the treatment of relapsed/refractory DLBCL globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Axicabtagene Ciloleucel Development
Founded Kite Pharma and drove development of axi-cel from NCI technology license through ZUMA-1 trial to FDA approval in 2017, establishing the first commercial CAR-T for aggressive lymphoma.
CAR-T Commercialization Model
Built the manufacturing and regulatory infrastructure for commercial CAR-T delivery, with Kite acquired by Gilead for $11.9B, catalyzing global investment in cellular immunotherapy.
Representative Works 代表性著作
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (ZUMA-1)
New England Journal of Medicine (2017)
Phase 1-2 trial demonstrating 82% objective response rate and 54% complete response in refractory large B cell lymphoma with axi-cel.
Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Nature Medicine (2019)
Long-term follow-up of ZUMA-1 showing durable complete responses in a substantial fraction of patients with refractory DLBCL.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 阿里·贝尔德格伦 的研究动态
Follow Arie S. Belldegrun's research updates
留下邮箱，当我们发布与 Arie S. Belldegrun（UCLA / Kite Pharma (Founder)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment